Work

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

Year: 2016

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(16)30558-7

Authors: Francesco Passamonti, Martin Griesshammer, Francesca Palandri, Miklos Egyed, Giulia Benevolo, Timothy Devos, Jeannie Callum, Alessandro M Vannucchi, Serdar Sivgin, Caroline Bensasson, Mahmudul Khan, Nadjat Mounedji, Guray Saydam

Institutions: University of Insubria, Johannes Wesling Klinikum Minden, University of Bologna, Somogy Megyei Kaposi Mór Oktató Kórház, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, KU Leuven, Sunnybrook Health Science Centre, University of Florence, Erciyes University, Novartis (United States), Novartis (France), Ege University

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Novartis Pharmaceuticals Corporation

OpenAlex ID: W2559562829

FWCI: 17.96

Cites: 35

Cited by: 273

Related to: 10